Celyad Treats First Patient of Second Cohort in NKG2D CAR T-Cell Phase I Trial
MONT-SAINT-GUIBERT, Belgium, Dec. 1, 2015 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno- …